Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.39 |
| ▸ | MAOB | P27338 | 2/20 | 0.38 |
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 6/20 | 0.36 |
| ▸ | HTR2C | P28335 | 6/20 | 0.36 |
| ▸ | IDO1 | P14902 | 1/20 | 0.35 |
| ▸ | HTR1D | P28221 | 2/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
| ▸ | CNR1 | P21554 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20204827 | 0.94 | CYP2D6 (0.43) | CYP2D6CYP1A2CYP2C19MAOBMAOA | |
| SCHEMBL20204830 | 0.90 | CYP2D6 (0.38) | CYP2D6CYP1A2CYP2C19IDO1HTR1D | |
| SCHEMBL20207840 | 0.84 | CYP2D6 (0.42) | CYP2D6CYP1A2CYP2C19 | |
| SCHEMBL24019545 | 0.81 | HTR2A (0.42) | CYP2D6CYP1A2CYP2C19MAOBMAOA | |
| SCHEMBL18374089 | 0.79 | MAOB (0.40) | MAOBMAOAHTR2AHTR2C | |
| SCHEMBL20207510 | 0.79 | CYP2D6 (0.40) | CYP2D6CYP1A2CYP2C19IDO1HTR1D | |
| SCHEMBL20207798 | 0.77 | CYP2C19 (0.38) | CYP2D6CYP1A2CYP2C19MAOBHTR2A | |
| SCHEMBL23052673 | 0.77 | MAOB (0.38) | MAOBMAOAHTR2AHTR2C | |
| SCHEMBL20204901 | 0.76 | MAOB (0.40) | MAOBMAOAHTR2AHTR2C | |
| SCHEMBL22170138 | 0.76 | MAOB (0.40) | MAOBMAOAHTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230263773-A1 | COMBINATION THERAPY WITH DEOXYURIDINE TRIPHOSPHATASE INHIBITORS | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2023-08-24 | — | — | US | disclosed |
| US-20230263773-A1 | COMBINATION THERAPY WITH DEOXYURIDINE TRIPHOSPHATASE INHIBITORS | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2023-08-24 | — | — | US | disclosed |
| US-20230126280-A1 | HYDANTOIN CONTAINING DEOXYURIDINE TRIPHOSPHATASE INHIBITORS | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2023-04-27 | — | — | US | disclosed |
| US-20230126280-A1 | HYDANTOIN CONTAINING DEOXYURIDINE TRIPHOSPHATASE INHIBITORS | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2023-04-27 | — | — | US | disclosed |
| US-11584723-B2 | Hydantoin containing deoxyuridine triphosphatase inhibitors | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2023-02-21 | — | — | US | disclosed |
| US-20220402879-A1 | HYDANTOIN CONTAINING DEOXYURIDINE TRIPHOSPHATASE INHIBITORS | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2022-12-22 | — | — | US | disclosed |
| US-11247984-B2 | Uracil containing compounds | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2022-02-15 | — | — | US | disclosed |
| US-10829457-B2 | Nitrogen ring linked deoxyuridine triphosphatase inhibitors | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2020-11-10 | — | — | US | disclosed |
| US-20200255385-A1 | HYDANTOIN CONTAINING DEOXYURIDINE TRIPHOSPHATASE INHIBITORS | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2020-08-13 | — | — | US | disclosed |
| US-10570100-B2 | Deoxyuridine triphosphatase inhibitors containing amino sulfonyl linkage | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2020-02-25 | — | — | US | disclosed |
| US-20190330210-A1 | HYDANTOIN CONTAINING DEOXYURIDINE TRIPHOSPHATASE INHIBITORS | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2019-10-31 | — | — | US | disclosed |
| US-20190276410-A1 | NITROGEN RING LINKED DEOXYURIDINE TRIPHOSPHATASE INHIBITORS | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2019-09-12 | — | — | US | disclosed |
| US-20180201586-A1 | DEOXYURIDINE TRIPHOSPHATASE INHIBITORS CONTAINING CYCLOPROPANO LINKAGE | SAI LIFE SCIENCES LIMITED (IN) | 2018-07-19 | — | — | US | disclosed |
| US-20180201586-A1 | DEOXYURIDINE TRIPHOSPHATASE INHIBITORS CONTAINING CYCLOPROPANO LINKAGE | SAI LIFE SCIENCES LIMITED (IN) | 2018-07-19 | — | — | US | disclosed |
| US-20180194740-A1 | DEOXYURIDINE TRIPHOSPHATASE INHIBITORS CONTAINING AMINO SULFONYL LINKAGE | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2018-07-12 | — | — | US | disclosed |
| US-20180194740-A1 | DEOXYURIDINE TRIPHOSPHATASE INHIBITORS CONTAINING AMINO SULFONYL LINKAGE | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2018-07-12 | — | — | US | disclosed |
| US-20180194736-A1 | HYDANTOIN CONTAINING DEOXYURIDINE TRIPHOSPHATASE INHIBITORS | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2018-07-12 | — | — | US | disclosed |
| WO-2018098204-A1 | 6-MEMBERED URACIL ISOSTERES | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2018-05-31 | — | — | WO | disclosed |
| WO-2018098209-A1 | AMINO SULFONYL COMPOUNDS | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2018-05-31 | — | — | WO | disclosed |
| WO-2018098208-A1 | NITROGEN RING LINKED DEOXYURIDINE TRIPHOSPHATASE INHIBITORS | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2018-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180194736-A1 | HYDANTOIN CONTAINING DEOXYURIDINE TRIPHOSPHATASE INHIBITORS | DUT, TYMP, DPYD | CYP2D6 2162/4885CYP1A2 3197/4885CYP2C19 3039/4885 |
| US-11584723-B2 | Hydantoin containing deoxyuridine triphosphatase inhibitors | DUT, TYMP, DPYD | CYP2D6 2162/4885CYP1A2 3197/4885CYP2C19 3039/4885 |
| US-20180194740-A1 | DEOXYURIDINE TRIPHOSPHATASE INHIBITORS CONTAINING AMINO SULFONYL LINKAGE | DUT, DPYD, TYMP | CYP2D6 2144/4885CYP1A2 4197/4885CYP2C19 4025/4885 |
| US-20220402879-A1 | HYDANTOIN CONTAINING DEOXYURIDINE TRIPHOSPHATASE INHIBITORS | DUT, TYMP, DPYD | CYP2D6 2162/4885CYP1A2 3197/4885CYP2C19 3039/4885 |
| US-20230263773-A1 | COMBINATION THERAPY WITH DEOXYURIDINE TRIPHOSPHATASE INHIBITORS | TYMP, DUT, TYMS | CYP2D6 1731/4885CYP1A2 3108/4885CYP2C19 3351/4885 |
| US-20190330210-A1 | HYDANTOIN CONTAINING DEOXYURIDINE TRIPHOSPHATASE INHIBITORS | DUT, TYMP, DPYD | CYP2D6 2162/4885CYP1A2 3197/4885CYP2C19 3039/4885 |
| US-10829457-B2 | Nitrogen ring linked deoxyuridine triphosphatase inhibitors | DUT, DPYD, TYMP | CYP2D6 2135/4885CYP1A2 2858/4885CYP2C19 3091/4885 |
| US-20200255385-A1 | HYDANTOIN CONTAINING DEOXYURIDINE TRIPHOSPHATASE INHIBITORS | DUT, TYMP, DPYD | CYP2D6 2162/4885CYP1A2 3197/4885CYP2C19 3039/4885 |
| US-11247984-B2 | Uracil containing compounds | UNG, DPYD, DUT | CYP2D6 1542/4885CYP1A2 3165/4885CYP2C19 2805/4885 |
| US-20190276410-A1 | NITROGEN RING LINKED DEOXYURIDINE TRIPHOSPHATASE INHIBITORS | DUT, DPYD, TYMP | CYP2D6 2135/4885CYP1A2 2858/4885CYP2C19 3091/4885 |
| US-20180201586-A1 | DEOXYURIDINE TRIPHOSPHATASE INHIBITORS CONTAINING CYCLOPROPANO LINKAGE | DUT, DPYD, TYMP | CYP2D6 1531/4885CYP1A2 2605/4885CYP2C19 3438/4885 |
| US-10570100-B2 | Deoxyuridine triphosphatase inhibitors containing amino sulfonyl linkage | DUT, DPYD, TYMP | CYP2D6 2144/4885CYP1A2 4197/4885CYP2C19 4025/4885 |
| US-20230126280-A1 | HYDANTOIN CONTAINING DEOXYURIDINE TRIPHOSPHATASE INHIBITORS | DUT, TYMP, DPYD | CYP2D6 2162/4885CYP1A2 3197/4885CYP2C19 3039/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.